Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-Linear-accelerator (MR-Linac): A prospective R-IDEAL Stage 0-2a quantitative/qualitative evaluation of in vivo site-specific quality-assurance using a 3D T2 fat-suppressed platform for head and neck cancer

Travis C. Salzillo, M. Alex Dresner, Ashley Way, Kareem A. Wahid, Brigid A. McDonald, Sam Mulder, Mohamed A. Naser, Renjie He, Yao Ding, Alison Yoder, Sara Ahmed, Kelsey L. Corrigan, Gohar S. Manzar, Lauren Andring, Chelsea Pinnix, R. Jason Stafford, Abdallah S.R. Mohamed, John Christodouleas, Jihong Wang, Clifton David Fuller
doi: https://doi.org/10.1101/2022.06.24.22276839

Article Information

doi 
https://doi.org/10.1101/2022.06.24.22276839
History 
  • June 27, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Travis C. Salzillo1,*,
  2. M. Alex Dresner2,
  3. Ashley Way1,
  4. Kareem A. Wahid1,
  5. Brigid A. McDonald1,
  6. Sam Mulder1,
  7. Mohamed A. Naser1,
  8. Renjie He1,
  9. Yao Ding3,
  10. Alison Yoder1,
  11. Sara Ahmed1,
  12. Kelsey L. Corrigan1,
  13. Gohar S. Manzar1,
  14. Lauren Andring1,
  15. Chelsea Pinnix1,
  16. R. Jason Stafford4,
  17. Abdallah S.R. Mohamed1,
  18. John Christodouleas5,
  19. Jihong Wang3 and
  20. Clifton David Fuller1
  1. 1Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
  2. 2Philips Healthcare, Cleveland, Ohio, USA
  3. 3Radiation Physics, MD Anderson Cancer Center, Houston, TX, USA
  4. 4Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA
  5. 5Elekta AB, Stockholm, Sweden
  1. ↵* Corresponding author; email: travis.salzillo92{at}gmail.com
Back to top
Posted June 27, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-Linear-accelerator (MR-Linac): A prospective R-IDEAL Stage 0-2a quantitative/qualitative evaluation of in vivo site-specific quality-assurance using a 3D T2 fat-suppressed platform for head and neck cancer
Travis C. Salzillo, M. Alex Dresner, Ashley Way, Kareem A. Wahid, Brigid A. McDonald, Sam Mulder, Mohamed A. Naser, Renjie He, Yao Ding, Alison Yoder, Sara Ahmed, Kelsey L. Corrigan, Gohar S. Manzar, Lauren Andring, Chelsea Pinnix, R. Jason Stafford, Abdallah S.R. Mohamed, John Christodouleas, Jihong Wang, Clifton David Fuller
medRxiv 2022.06.24.22276839; doi: https://doi.org/10.1101/2022.06.24.22276839
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area